Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Splenic artery

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Splenic artery. Displaying page 1 of 1.
    EudraCT Number: 2011-001472-18 Sponsor Protocol Number: UDT-2/PHT Start Date*: 2011-05-10
    Sponsor Name:STZ 1172 Gesundheitsförderung und Stoffwechselforschung
    Full Title: Double-Blind, Randomised, Cross-Over, Placebo-Controlled, Single-Centre Phase IIa Clinical Study on the Influence of Udenafil on the Portal Flow in Cirrhotic Patients with Portal Hypertension
    Medical condition: Portal hypertension, liver cirrhosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002208-21 Sponsor Protocol Number: TP-434-025 Start Date*: 2016-09-27
    Sponsor Name:Tetraphase Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Meropenem in Complicated Intra-abdominal Infections
    Medical condition: Complicated Intra-abdominal Infections
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) LV (Completed) EE (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-001913-34 Sponsor Protocol Number: TP-434-008 Start Date*: 2013-08-16
    Sponsor Name:Tetraphase Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Ertapenem in Complicated Intra-abdominal Infections
    Medical condition: Complicated Intra-abdominal Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) EE (Completed) LT (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-002196-34 Sponsor Protocol Number: Neo.Lu.Pa.NET Start Date*: 2019-11-07
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE Followed by Surgery for resectable Pancreatic Neuroendocrine Tumors (Neo.Lu.Pa.NET)
    Medical condition: Resectable pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000345-46 Sponsor Protocol Number: CRC2017_01 Start Date*: 2017-11-22
    Sponsor Name:CENTRO RICERCHE CLINICHE DI VERONA
    Full Title: A Phase II Study of Liposomial IrinoTecan (nal-IRI) with 5-Fluorouracil, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer ¿nITRo trial"
    Medical condition: Resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001320-19 Sponsor Protocol Number: CTX001-121 Start Date*: 2018-12-05
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sick...
    Medical condition: Severe Sickle Cell Disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006393-14 Sponsor Protocol Number: UDT-1/PHT Start Date*: 2007-10-23
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, Multi-Centre Phase II Clinical Study on the Efficacy and Safety of Different Doses of Udenafil in Cirrhotic Patients with Portal Hypert...
    Medical condition: Portal hypertension, liver cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10019805 - Hepatobiliary disorders 10036200 Portal hypertension PT
    13.1 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000811-12 Sponsor Protocol Number: ST03 Start Date*: 2008-01-31
    Sponsor Name:Medical Research Council Clinical Trials Unit
    Full Title: A Randomised Phase II/III trial of peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive...
    Medical condition: Patients with histologically verfied lower oesophageal, Siewert Type I, II or III oesophagogastric junction or gastric adenocarcinoma. Type III or gastric tumours should be stage 1b (T1N1, T2a/bN0...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 07:12:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA